ALYFTREK DIN 02559676
Status: Marketed
Holder: VERTEX PHARMACEUTICALS (CANADA) INCORPORATED
Molecule: VANZACAFTOR (VANZACAFTOR CALCIUM)
Health Canada record
| Active ingredient(s) | VANZACAFTOR (VANZACAFTOR CALCIUM) 4 MG; TEZACAFTOR 20 MG; DEUTIVACAFTOR 50 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | R07AX OTHER RESPIRATORY SYSTEM PRODUCTS |
| Original market date | 31-Jul-2025 |
| Current status date | 31-Jul-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Vertex Pharmaceuticals (Canada) Incorporated — licence 101886, currently licensed, last inspection rating C (2024-07-30).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VANZACAFTOR (VANZACAFTOR CALCIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02559684 | ALYFTREK | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED | Tablet | VANZACAFTOR (VANZACAFTOR CALCIUM) 10 MG; TEZACAFTOR 50 MG; DEUTIVACAFTOR 125 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 35709 | 2025-07-21 | New Drug Submission (NDS) |